Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. - Wikidata - awgldk - TriplyDB

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.

http://www.wikidata.org/entity/Q33657377

about

Immune Mechanisms in Myelodysplastic Syndrome Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes The Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor Efficacy Pembrolizumab in classical Hodgkin's lymphoma Established and emerging targeted therapies in the myelodysplastic syndromes.Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies.Immune checkpoint blockade for hematologic malignancies: a review Checkpoint inhibitors in hematological malignancies Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia.Epigenetic Strategies to Boost Cancer Immunotherapies.Augmenting antitumor immune responses with epigenetic modifying agents.Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation.Identification of Novel HLA-A*24:02-Restricted Epitope Derived from a Homeobox Protein Expressed in Hematological Malignancies.PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation.T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330.Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents.Programmed death-1 checkpoint blockade in acute myeloid leukemia.Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.Chronic myelomonocytic leukemia: Forefront of the field in 2015.Promoter Hypomethylation and Expression Is Conserved in Mouse Chronic Lymphocytic Leukemia Induced by Decreased or Inactivated Dnmt3a.Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy.Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.Hypomethylating agents after allogeneic blood stem cell transplantation.Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies.Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma.The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation.Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities.Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution.The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment.The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.New treatment for acute myelogenous leukemia.Ezatiostat hydrochloride for the treatment of myelodysplastic syndromes.Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia.Preparing Patients With Myelodysplastic Syndrome for Transplant When Is Pre-transplant Cytoreductive Therapy Appropriate?

P2860

Q26744500-A5E215E1-62C0-432E-AB31-AB70EB57F08D Q26749870-1FE89E09-BCED-42B4-B065-5BEA76487EFF Q26766066-81432F9E-75A9-4FE5-BA85-A59B9CB4D9A3 Q26770391-79D99C17-0478-4F5E-942D-0D8246E5EAD3 Q26796240-5CA8D4D9-99C0-45FD-82D2-6ABFBA9F6E33 Q27015288-C0E065EF-8D8D-445F-92C6-7B0CC1DF5C6E Q28076473-4A1B0D28-E532-4483-BA64-2AB661113164 Q28079273-19BDCE32-2CF0-4BE8-BECA-D85C1D719071 Q30245476-EBF42C29-8088-49E4-B471-A84F3C10EB94 Q33638083-0033C1C8-847F-4A4E-87EA-620B7FEA5D80 Q33645590-61EC7A00-F32F-4496-B7DF-D353A8C966AB Q33651495-9E10C00C-B3B4-436D-9C1F-C747C5C80A9E Q33814411-D6B1A1B1-FD18-427F-9279-2C7D6652C199 Q33838340-8C6A848C-0DB9-4907-93F7-546A30154921 Q35048054-FFD80FBA-EBFE-4CD1-BF13-C0542C6AC6D3 Q35752467-77A6A52D-F035-4F0B-A30E-AC0434780C43 Q35832463-910C5281-430C-447E-9ADF-F48742FFC294 Q35897592-9934E811-FFD5-4246-BAF0-C17C6ED7E611 Q35921900-6743D32B-72E4-4236-82C9-240C6E701891 Q36022539-ACB246C8-20DE-4EC4-85B8-997F2F0917AA Q36627526-F01CD4F6-FFFF-4856-B01B-A51F988B086C Q36652124-BC9F2BAD-92B0-458A-91EC-7AC2E192CE2A Q36700481-117F34C0-BCD5-4A27-9E83-7C8A835D650C Q36876853-B88CBA4B-2BC7-4177-86F3-1116EDDA5ADA Q36892794-FCED9240-B1CD-43D0-A858-6025E6B2BDDE Q37022306-B12A299C-138C-44AD-881A-BAFD8CE8B3D5 Q37066925-3A32D602-D065-4E72-898C-F377F21A7216 Q37517482-E213D4D1-2CA6-4EA8-A172-42A45EDBC4D6 Q37531039-789B891E-DB3A-45DC-9A63-D416C6ABCF92 Q37587362-37206CA1-9F5D-49FD-BFB5-C7B314D00CB0 Q37589140-1B200983-37CF-4230-8ED4-C885B2BFB230 Q37731703-D02D567F-D854-47FA-8743-74BEECA04085 Q37737945-AC612967-F283-4B39-A352-D60A796178CB Q38218055-DE3E5144-CC4C-4F8A-A3C1-197D7CE34E9D Q38250205-3F8D0BFB-3032-4F3B-9816-B2D4A8041D4A Q38261285-5453F68E-29CE-4D0E-9FE0-4FA54E682C7D Q38284045-41F386A7-E814-447A-BBD4-721C6050CBE9 Q38365967-4F516FF4-6887-406A-9455-E4791E710031 Q38485334-3B4B2807-9193-419B-860A-E4D1BF7EC70A Q38540862-5F1E7022-D70F-4ED9-9DC4-86E214CB71F1

P2860

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.

http://www.wikidata.org/entity/Q33657377

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Expression of PD-L1, PD-L2, PD ...... t with hypomethylating agents.

@ast

Expression of PD-L1, PD-L2, PD ...... t with hypomethylating agents.

@en

type

label

Expression of PD-L1, PD-L2, PD ...... t with hypomethylating agents.

@ast

Expression of PD-L1, PD-L2, PD ...... t with hypomethylating agents.

@en

prefLabel

Expression of PD-L1, PD-L2, PD ...... t with hypomethylating agents.

@ast

Expression of PD-L1, PD-L2, PD ...... t with hypomethylating agents.

@en

P1433

Q33657377-BB1631FA-0DEE-4789-B7B0-29FC3AB1A9FE

P1476

Q33657377-5E3956B5-D7B1-48E0-BE5F-CE6A87285640

P2093

Q33657377-1FCE94D2-EFBF-43A0-B773-12C708E89AED

Q33657377-2CFAD0D9-20EB-42B0-8A90-590CA924F27B

Q33657377-37BD2E14-94D9-487B-85A5-E88299A4BEDA

Q33657377-6DE073C4-E019-42B7-995D-3A3C8272EAA8

Q33657377-77499A13-E192-4463-B452-D4C0F0EFA4C0

Q33657377-7B639BEC-242F-4219-A01D-E482F8951441

Q33657377-855F38C4-1790-4E2B-AD08-41FE232FF9FE

Q33657377-876D7126-6F8C-49E9-8B7A-4298D2C146B6

Q33657377-9F4488AE-C61B-4251-8EA0-E8334650D68D

Q33657377-E63B5AE3-2DB7-4454-B355-441FAD29C35A

P2860

Q33657377-02AB36B5-928B-431A-B3B4-E6762C032E76

Q33657377-037E4018-C8DB-43F3-A2DD-A81140A9B28A

Q33657377-0FFF1266-1292-46D5-934B-A3EB8F8BE1E4

Q33657377-171D3B09-9278-4306-9D6E-EB7107774814

Q33657377-172D5C4D-C507-48DB-8AD5-4653ABD7DF51

Q33657377-1FF3BA6A-3500-4142-A8C5-8BB4DB012AF2

Q33657377-476B495B-1465-4B69-9DE3-DB955C88252C

Q33657377-4EFDA127-3D21-499C-B3B6-C0707BF40342

Q33657377-507C70D5-C009-40E0-8900-CB9C15F5C95C

Q33657377-585CA3D5-2F60-46BB-85DF-E537D5CEE7DC

P2888

Q33657377-684A9763-3C49-4204-949F-4516F02097DB

P304

Q33657377-661A1155-40E3-405E-A34E-CA8D8F0CA28D

P31

Q33657377-6C9BDFF7-6577-49B0-8C5C-BC674223D650

P356

Q33657377-2441118A-F97D-427E-B1DE-F41DAD2A316A

P433

Q33657377-3987C4AD-DF1A-4006-B335-1AD974F16F7C

P478

Q33657377-2ABFB896-F70E-4AF1-B134-F4ABE87188FC

P50

Q33657377-0A311534-602E-47F2-B6E6-87B874AF27E5

P577

Q33657377-FE388513-D471-4F7E-A89B-B51C90FA7E00

P5875

Q33657377-72FF83E2-66C8-4120-9FF4-A1D29CD68611

P6179

Q33657377-0AC45AC8-CAB0-4D55-B7E9-3E7DFED4EFDC

P698

Q33657377-A65BA3C8-984E-47F8-9805-E1BC137DFD48

P932

Q33657377-76F0AA96-2FF3-4F00-9575-5ECCEE60419A

P356

P1433

P1476

Expression of PD-L1, PD-L2, PD ...... nt with hypomethylating agents

@en

P2093

C Bueso-Ramos

http://www.w3.org/2001/XMLSchema#string

C DiNardo

http://www.w3.org/2001/XMLSchema#string

G Garcia-Manero

http://www.w3.org/2001/XMLSchema#string

H Kantarjian

http://www.w3.org/2001/XMLSchema#string

H Yang

http://www.w3.org/2001/XMLSchema#string

J Cortes

http://www.w3.org/2001/XMLSchema#string

M Davanlou

http://www.w3.org/2001/XMLSchema#string

M Nguyen

http://www.w3.org/2001/XMLSchema#string

Q-R Geng

http://www.w3.org/2001/XMLSchema#string

S Parmar

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

Myeloid-derived suppressor cells as regulators of the immune system

PD-1 and its ligands in tolerance and immunity

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

International scoring system for evaluating prognosis in myelodysplastic syndromes

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

Myelodysplastic syndromes: the role of the immune system in pathogenesis.

Clinical effect of point mutations in myelodysplastic syndromes

P2888

P304

1280-1288

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2013.355

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-11-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258854757

http://www.w3.org/2001/XMLSchema#string

P6179

1016638535

http://www.w3.org/2001/XMLSchema#string

P698

24270737

http://www.w3.org/2001/XMLSchema#string

P932

4032802

http://www.w3.org/2001/XMLSchema#string